Skip to main content
NCBI home page
Netherlands Heart Journal logoLink to Netherlands Heart Journal
. 2004 Nov;12(11):512–515.

Heart failure: chapter 6. Pharmacological treatment of chronic heart failure

AA Voors, PHJM Dunselman, DJ van Veldhuisen
PMCID: PMC2497407  PMID: 25696279

Full text

PDF
512

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cohn J. N., Archibald D. G., Ziesche S., Franciosa J. A., Harston W. E., Tristani F. E., Dunkman W. B., Jacobs W., Francis G. S., Flohr K. H. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1986 Jun 12;314(24):1547–1552. doi: 10.1056/NEJM198606123142404. [DOI] [PubMed] [Google Scholar]
  2. Cohn J. N., Johnson G., Ziesche S., Cobb F., Francis G., Tristani F., Smith R., Dunkman W. B., Loeb H., Wong M. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991 Aug 1;325(5):303–310. doi: 10.1056/NEJM199108013250502. [DOI] [PubMed] [Google Scholar]
  3. Cohn J. N., Tognoni G., Valsartan Heart Failure Trial Investigators A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001 Dec 6;345(23):1667–1675. doi: 10.1056/NEJMoa010713. [DOI] [PubMed] [Google Scholar]
  4. Cohn J. N., Ziesche S., Smith R., Anand I., Dunkman W. B., Loeb H., Cintron G., Boden W., Baruch L., Rochin P. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Circulation. 1997 Aug 5;96(3):856–863. doi: 10.1161/01.cir.96.3.856. [DOI] [PubMed] [Google Scholar]
  5. Guyatt G. H. The treatment of heart failure. A methodological review of the literature. Drugs. 1986 Dec;32(6):538–568. doi: 10.2165/00003495-198632060-00004. [DOI] [PubMed] [Google Scholar]
  6. Hjalmarson A., Goldstein S., Fagerberg B., Wedel H., Waagstein F., Kjekshus J., Wikstrand J., El Allaf D., Vítovec J., Aldershvile J. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA. 2000 Mar 8;283(10):1295–1302. doi: 10.1001/jama.283.10.1295. [DOI] [PubMed] [Google Scholar]
  7. Køber L., Torp-Pedersen C., Carlsen J. E., Bagger H., Eliasen P., Lyngborg K., Videbaek J., Cole D. S., Auclert L., Pauly N. C. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med. 1995 Dec 21;333(25):1670–1676. doi: 10.1056/NEJM199512213332503. [DOI] [PubMed] [Google Scholar]
  8. O'Connor C. M., Carson P. E., Miller A. B., Pressler M. L., Belkin R. N., Neuberg G. W., Frid D. J., Cropp A. B., Anderson S., Wertheimer J. H. Effect of amlodipine on mode of death among patients with advanced heart failure in the PRAISE trial. Prospective Randomized Amlodipine Survival Evaluation. Am J Cardiol. 1998 Oct 1;82(7):881–887. doi: 10.1016/s0002-9149(98)00496-2. [DOI] [PubMed] [Google Scholar]
  9. Packer M., Coats A. J., Fowler M. B., Katus H. A., Krum H., Mohacsi P., Rouleau J. L., Tendera M., Castaigne A., Roecker E. B. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001 May 31;344(22):1651–1658. doi: 10.1056/NEJM200105313442201. [DOI] [PubMed] [Google Scholar]
  10. Pfeffer M. A., Braunwald E., Moyé L. A., Basta L., Brown E. J., Jr, Cuddy T. E., Davis B. R., Geltman E. M., Goldman S., Flaker G. C. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992 Sep 3;327(10):669–677. doi: 10.1056/NEJM199209033271001. [DOI] [PubMed] [Google Scholar]
  11. Pfeffer Marc A., McMurray John J. V., Velazquez Eric J., Rouleau Jean-Lucien, Køber Lars, Maggioni Aldo P., Solomon Scott D., Swedberg Karl, Van de Werf Frans, White Harvey. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003 Nov 10;349(20):1893–1906. doi: 10.1056/NEJMoa032292. [DOI] [PubMed] [Google Scholar]
  12. Pitt B., Zannad F., Remme W. J., Cody R., Castaigne A., Perez A., Palensky J., Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999 Sep 2;341(10):709–717. doi: 10.1056/NEJM199909023411001. [DOI] [PubMed] [Google Scholar]
  13. Pitt Bertram, Remme Willem, Zannad Faiez, Neaton James, Martinez Felipe, Roniker Barbara, Bittman Richard, Hurley Steve, Kleiman Jay, Gatlin Marjorie. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003 Mar 31;348(14):1309–1321. doi: 10.1056/NEJMoa030207. [DOI] [PubMed] [Google Scholar]
  14. Poole-Wilson Philip A., Swedberg Karl, Cleland John G. F., Di Lenarda Andrea, Hanrath Peter, Komajda Michel, Lubsen Jacobus, Lutiger Beatrix, Metra Marco, Remme Willem J. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003 Jul 5;362(9377):7–13. doi: 10.1016/S0140-6736(03)13800-7. [DOI] [PubMed] [Google Scholar]
  15. de Vries R. J., van Veldhuisen D. J., Dunselman P. H. Efficacy and safety of calcium channel blockers in heart failure: focus on recent trials with second-generation dihydropyridines. Am Heart J. 2000 Feb;139(2 Pt 1):185–194. doi: 10.1067/mhj.2000.101490. [DOI] [PubMed] [Google Scholar]

Articles from Netherlands Heart Journal are provided here courtesy of Springer

RESOURCES